Real-world use of bezlotoxumab to prevent recurrent infections: a single-center experience and meta-analysis

Real-world use of bezlotoxumab to prevent recurrent infections: a single-center experience and meta-analysis

Background: Clostridioides difficile infection (CDI) treated with bezlotoxumab (BEZ) has been demonstrated to have a lower recurrence rate than placebo in clinical trials. However, real-world data on BEZ’s effectiveness remain limited and heterogeneous. Objectives: To evaluate the real-world effecti...

Full description

Saved in:
Bibliographic Details
Main Authors: Kanika Sehgal, Parul Berry, Raseen Tariq, Darrell S. Pardi, Sahil Khanna
Format: Article
Language:English
Published: SAGE Publishing 2025-06-01
Series:Therapeutic Advances in Gastroenterology
Online Access:https://doi.org/10.1177/17562848251346593
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items